Why Two Smoking Cessation Agents Work Better than One: Role of Craving Suppression

Autor/inn/en	Bolt, Daniel M.; Piper, Megan E.; Theobald, Wendy E.; Baker, Timothy B.
Titel	Why Two Smoking Cessation Agents Work Better than One: Role of Craving Suppression
Quelle	In: Journal of Consulting and Clinical Psychology, 80 (2012) 1, S.54-65 (12 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0022-006X
DOI	10.1037/a0026366
Schlagwörter	Smoking; Individual Counseling; Data Collection; Medicine; Research; Drug Therapy; Models; Behavior Patterns; Psychological Patterns; Measures (Individuals); Intervention; Behavior Modification; Outcomes of Treatment; Adults; Males; Females + Suchen Sie Ihr Suchwort? Rauchen; Data capture; Datensammlung; Medizin; Forschung; Analogiemodell; Messdaten; Behaviour modification; Verhaltensänderung; Male; Männliches Geschlecht; Weibliches Geschlecht
Abstract	Objective: This research examined why smokers receiving combination medication for smoking cessation are more likely to quit smoking than are those who receive either single agent (monotherapy) or placebo. Method: Data were collected from 1,504 current smokers (58.2% women, 83.9% White; mean age = 44.67 years, SD = 11.08) participating in a cessation clinical trial who were randomized to 1 of 6 cessation pharmacotherapy conditions (placebo, nicotine patch, nicotine lozenge, bupropion, nicotine patch + nicotine lozenge, and bupropion + nicotine lozenge). Participants completed ecological momentary assessments 4 times a day, concerning 5 hypothesized mediators (negative affect, positive affect, craving, smoking expectations, and withdrawal) of pharmacotherapy effects. Medications were provided for 8-12 weeks post-quit along with 6 individual counseling sessions. Mediational paths were estimated via a novel Bayesian approach with estimation of multiple mediator models. Results: Biochemically confirmed 8-week abstinence was the outcome variable, with the monotherapy and combination pharmacotherapy composites producing 45% (n = 689) and 54% (n = 478) abstinence rates, respectively. The univariate models suggested that the combination treatments produced higher abstinence rates than the monotherapies because of greater suppression of withdrawal, craving, and smoking expectations. However, multiple mediator models showed that the suppression of craving on the quit day produced the strongest mediational effects and could account for the mediational effects of other tested variables. Conclusion: Suppression of craving on the quit day significantly mediates the clinical effects of monotherapies and combination smoking pharmacotherapies, and the higher abstinence rates for combination therapy versus monotherapies appear primarily due to greater craving suppression. (Contains 5 footnotes, 4 tables, and 1 figure.) (As Provided).
Anmerkungen	American Psychological Association. Journals Department, 750 First Street NE, Washington, DC 20002-4242. Tel: 800-374-2721; Tel: 202-336-5510; Fax: 202-336-5502; e-mail: order@apa.org; Web site: http://www.apa.org/publications
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10